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ABSTRACT
Parkinson's disease (PD) is a common progressive neurological
disorder. It affects the central nervous system by depleting the basal ganglia
of dopamine. To date, the standard treatment is drug therapy to replace the
lacking dopamine. However, this treatment is problematic as there are many
side effects to the drugs. Also, this treatment does not effect the progression
of this disease. Therefore, drug therapy becomes continuously less effective
in treating PD. For this reason, new fonns of therapy are being researched
for the treatment of advanced PD. One of the most recent therapeutic
interventions is fetal tissue transplantation.
The purpose of the independent study is to review literahlre regarding
fetal tissue transplantation in PD. This study will include a brief overview of
the pathophysiology and current treatment methods for PD. Also, an
overview of the history of neural transplantation for PD will be presented. In
addition, the paper will include a discussion of the ethical and legal issues
surrounding fetal tissue transplantation.
Physical therapists CPT) treat many patients with PD. In the future,
PT's maybe responsible for rehabilitating PD patients following fetal tissue
transplantation surgery. This paper may be used as a tool by PT's to gain a
greater understanding of a very innovative research technique.

CHAPTER 1
PD PATHOLOGY AND TREATMENT

In 1917 , James Parkinson published an essay about the shaking palsy.
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This disorder was subsequently named Parkinson's disease (PD). PD is a
debilitating neuro-muscular disease which presents with numerous
pathological movement symptoms. The disease affects the motor planning
areas of the brain. The primary manifistations are rigidity, bradykinesia, and
tremor. 2 ,3 PD causes an inability to initiate movements as well as a
characteristic "pill-roll" involuntarily tremor.2-4 PD also presents with flexed
posture, festinating gait and "cog-wheel" or "lead-pipe" rigidity. 3, 4 The
rigidity is different than that displayed in spasticity because there is an
increase in antagonist as well as agonist neuromuscular output. 3 PD also
decreases associated movements such as : normal ann swing during gait,
facial expressions, and gestures during conversation.2,3
The anatomical structures involved in PD include the basal ganglia and
the substantia nigra. The term basal ganglia is used to designate several
structures including the caudate nucleus, putamen, and globus pallidus. 3,4
These structures are intimately related to the cerebral cortex, thalamus, and
substantia nigra through networks of neurons. 4 The structures of the basal
ganglia are thought to be involved in the planning and programming of
voluntary movements.3
PD is referred to as the most common type of basal ganglia disease.2,4
Patho-physiology of the disease is characterized by massive degeneration of
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the substantia nigra. 4 There is also a depletion of dopamine, an inhibitory
neurotransmitter of the caudate nucleus and putamen. 4 This is caused by a
degeneration of the neurons of the basal gang1ia. I-4 This is a process of
nonnal aging, however in PD, this steady loss of dopamine is acce1erated. 3
Dopamine levels in persons with PD may be as low as 50% of normal. 3
With the degeneration of the basal ganglia and subsequent loss of
dopaminergic cells, the usual balance between excitatory acetylocholine and
inhibitory dopamine is disrupted. This imbalance leads to an impairment of
the control of smooth, voluntary movement. I
To date, the principle treatment for PD has been drug therapy to replace
the lacking dopamine. However, this has been problematic as dopamine
cannot cross the blood brain barrier (BBB). Dopamine is therefore
prescribed in the fonn of leva dopa (L-dopa), which will penetrate the BBB.I3 L-dopa is the metabolic precursor of dopamine.2. 3 L-dopa is combined
with a dopa-inhibitor (Sinamet or Madopar) to prevent it from being
converted to dopamine in the periphery.I-3
Treatment of PD with drug therapy has many undesirable side-effects.
These include nausea, vomiting, hallucinations, dizziness, and painful
spasms or cramps.l.2 There is also the development of the lion-off'
phenomenon or end-of-dose deterioration. This is a fluctuation in
performance and drug response.2 Fietcher l describes the on-off phenomenon
as periods of abnormal mobility, alternating with periods of complete
immobility. According to O'Sullivan 2, 50% of patients taking L-dopa for
more than two years experience the on-off phenomenon.
L-dopa therapy does not influence disease progression.l.2 \Vith the
advancement of the disease, drug therapy is less effective as the number of
dopamine producing cell decreases. I. 2 To continue to get the therapeutic
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effects of L-dopa, increasingly larger doses are required. l In time, patients
develop adverse side effects or become tolerant of the drug. S Patients with
decreased responsiveness to L-dopa may be put on "drug holiday".2.6 This is
a period of 7-10 days of transient withdrawal from the drug. 2 This may
enhance motor response to L-dopa and decrease the negative effects of the
drug.
Because the treatment of severe PD is so problematic, new forms of
therapy are being researched. One of the most innovative and often
controversial is neural transplantation, which will be discussed in chapter 2.

CHAPTER 2
HISTORY OF NEURAL TRANSPLANTATION

Neural transplantation, first perfonned in 1890, was initially perceived as
an experimental tool for the systematic study of neural development and
regeneration. 7 ,8 In contemporary science, neural transplantation is rapidly
becoming a potential treatment for some previously difficult diseases,
namely PD. Research on neural transplantation with respect to PD began
with extensive work utilizing animal models. This approach was then
adopted in human patients in 1985. According to Rosenfeld et a1,7 "Since
that time several hundred human transplants have been carried out for PD
with only limited success".
Two very different basic procedures have been done with neural
transplantation for severe PD. One method is to take dopamine
manufacturing cells from the adrenal medulla and place them directly into
the substantia nigra of that same individual. Bakay and Barrow 9 reviewed
eleven reports and found that this procedure has been perfonned 84 times
since 1985 with a 33 % incidence of major complications. This may be due
to the fact that three major procedures must be performed consecutively,
with as little time lapse as 10-12 hours. First, the tissue must be excised
from the adrenal medulla of the patient. Secondly, that tissue must be made
into a suspension. Finally, the tissue is then implanted into the substantia
nigra of the patient. Regarding adrenal medulla transplant, according to
Rosenfeld et al, 7 it has been found that "some patients have apparently
4
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improved significantly in the short tenn but this has not been sustained",
Further discussion of adrenal medullary grafts is beyond the focus of this
paper.
"Following the overall failure of adrenal medullary grafts, attention
swung toward the use of fetal tissue to replace damaged or lost neurons in
PD" ,8 With fetal tissue transplant, tissue from the mesencephalon of aborted
fetuses is made into a suspension and injected, through a frontal burr hole,
into the basal ganglia of a PD patient. The origin of the fetal tissue (from
voluntary abortions) is the cause of much ethical debate,
Collectively, the findings of the literature reviewed are contradictory,
Both inter and intra study results are inconsistent. Most patients showed
improvements which were of scientific relevance, however, because their
quality of life was not noticably changed, these patients did not view the
procedure as a success,8 The procedures and results of seven studies of
experimental fetal neural transplantation surgeries for PD will be reviewed
and discussed in the following chapter.

CHAPTER 3
FTT STUDIES REVIEWED

A Czechoslovakian experiment by Subrt et al 8 was published in 1991. In
this study, three patients with PD who received neural transplantation were
followed for one year. The patients were closely monitored for two months
prior to surgery. The surgery technique included transplantation of
mesencephalic tissue from 7-8 week old fetuses into three advanced PD
patients. A frontal burr hole was used to implant the tissue stereographically into the head of the caudate nucleus of the three patients. A
longer outer cannula was used to prepare the bed for the transplant. Then
fetal tissue was placed with a small inner cannula.
The three patients had immediate prolongation of On phase. 8 Other
improvements became apparent at approximately three months. Patients
became relieved of L-dopa side effects and doses were reduced. One patient
showed remarkable results. Before the procedure, she was bed-ridden and
symptoms could only be alleviated by intravenous anticholinergic drugs.
After surgery, she could eat alone and ambulate with a cane. The other two
patients L-dopa levels were reduced to 60% the pre-surgery dosage.
However, these two patients did not value their improvements as their
lifestyles did not change.
The research team has already begun to modify its procedure as other
studies are done. They anticipate that transplantation \vill be a viable
alternative to drug therapy.
6
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In a study by Henderson et al,lo 12 patients received Fetal Transplant
Tissue for advanced PD. Of the 12, nine patients were consistently followed
for 12 months post-operatively. All patients were at Hoehn-Yahr
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stage 4/5

(Table 1.) before surgery. The procedure was an injection of Fetal Tissue
through a right frontal burr hole into the caudate nucleus of each patient.
Twelve patients had surgery, three of which did not comply with the
follow-up schedule. Of the nine monitored for 12 months post-operative,
four" experienced immediate subj ective post-operative improvements" .10
Five patients had a mean decrease in levadopa dosage of 60% of their
previous levels at 12 months. One patient did not need levadopa treatment
at 12 months and another individual required only 10% of pre surgery
dosage. At one year, three patients deteriorated compared to pre-operative
assessment. Maximal changes were seen at six months after surgery. These
researchers concluded that there are many operations being done world-wide
and research will continue at the same rate as the "increasing understanding
of human fetal development and the patho genesis of PD" .10
In a study by Freed et al,6 seven patients who had advanced PD for 7-20
years received FTT. Patients ranged in age from 39-66 years old.
Preoperatively, five patients were rated a stage IV on the Hoehn-Yahr scale
and two patients were rated stage III. For all patients selected, dmg therapy
had failed and most were experiencing significant on-off phenomenon. This
included periods of complete immobility, falling and dyskinesia. Patients
were evaluated daily for four months to one year pre-surgery and 12-46
months post-surgery.
Fetal tissue, six to eight weeks old, was injected stereotaxically into as
many as nine needle tracts.6 This study focused on the putamen as the
transplant site. Patient one and two received grafts to the caudate and
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Stage I

Minimal unilateral Disbility

Stage II

Minimal disability either bilateral or midline

Stage III

Righting reflexes are impaired, patient
lives independently with some restrictions
in activities

Stage IV

Parkinson's manifestations are present and severe

Stage V

Patient is either bed or wheelchair bound
Table 1. Hoehn and Yahr PD Rating Scale 11
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putamen unilaterally. Patients three through seven had bilateral grafts to the
putamen only.
Overall, the group dropped an average of l.2 stages on the Hoehn-Yahr
scale with the greatest difference from a stage IV to a stage II postoperative. 6 The level of dopamine dosage dropped an average of 39% for
the seven patients. The largest decrease in dosage was 58%. Patient one, at
46 months, showed the greatest improvements in the contralateral hand. His
time spent in "on" phase went from 70 to 85 % of his day. Patient two
showed no clinical improvement over a 33 month examination period.
Patient three, at 21 months, had a reduction in periods of dyskinesia, as well
as, time spent in the "off' phase. This patient appeared normal at times and
had resumed social activities. Patient four had been followed for 13 months.
She regained control of her gait and did not fall as she had pre-operatively.
She was in the "on" phase 100% of the day, as compared to 65% of the day
before surgery. Patient five had, before surgery, experienced extreme on-off
phenomenon. At 12 months, the patient had a considerable reduction in
duration and severity of "off' phase and dyskinesia following surgery. This
patient was able to regain his driver's license. Patient six, at 12 months after
surgery, returned to his pre-operative level of function with improved
postural control and a marked decrease in bradykinesia. At 11 n10nths
following surgery, patient seven had normal movement for as much as 30%
of the day. Prior to surgery, he had no movement classified as nOlmal. This
patient went from sleeping only three hours per night before FTT to eight
hours after.
These authors stated that all patients in this study, made improvements in
the "On" phase. 6 Four of the patients, and their physicians, felt the gains
significantly changed their daily lives. These researchers contended that a
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placebo effect may be ruled out on the grounds that adrenal medullary graft
patients did not sustain their improvements. The authors concluded that FTT
may add a new dimension to the treatment of severe PD .
In a study by Spencer et al,12 four patients received FTT. The implants
were injected stereotaxically into the right caudate nucleus. The patients
needed three or four of the cardinal signs ofPD to be included in the study.
These signs were resting tremor, rigidity, bradykinesia and postural
instability. Also, the individual had to be at a Hoehr-Yahr stage IV.
The results of the study are discussed in the following paragraphs.
Patient one, pre-operatively, was house bound and unable to perfonn
activities of daily living.12 After surgery, she had gradual reduction in
bradykinesia, and rigidity, and improvements in gait ability. She also had
improvements in visual searching, visual memOlY, and cognitive testing.
However, after six months, all measures retunled to pre-operative baselines
with the exception of visual searching. Patient two was very involved preoperatively. Following surgery, he showed minimal gains in autonomic
functions. This patient died four months after receiving FTT. Post-mortum
examination documented that the FTT grafts showed a viable blood supply
and the formation of synaping neurons. Patient three presented with resting
tremor, rigidity, gait disorder and dysphasia before surgery. Following FTT,
this patient developed motor seizures, transient panic disorder, agoraphobia,
and major depression. These were all controlled with medications. The
patient had an increase in IQ test score of 14 points. Patient four was
significantly debilitated by the on-off phenomenon before receiving FTT.
He was unable to perform activities of daily living. Post-surgery, his trend
towards worsening rigidity and tremor stabilized. A one year follow-up
study showed an increase of nine points in his IQ.
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Overall, the most significant result was that patients· levadopa leve Is
decreased by 60%. The grafts were placed unilaterally in all patients,
however, there was no change in function between the two sides of the body.
The authors concluded that moderate bilaterally improvements were made in
specific motor tasks. However, the patients still remained markedly affected
by their disease according to the Hoehn-Yahr scale. These authors
concluded that it is difficult to compare FTT studies as research teams use
different procedures and evaluation methods. In addition, the procedure of
FTT IIremains highly investigational and should not yet be considered a
clinical treatment for PD. 1112
In an on-going study by Lindvall et al,13 a total of four patients have
received FTT for PD. A recently published article described the results of
one-year clinical observations of two of those patients (patients three and
four). The patients entered the study one year before surgery and were
followed for one year post-operatively. Patients self-monitored their n10tor
symptoms in a daily log every 30 minutes. The patients were also evaluated
every two weeks by the researchers for an eight hour period.
The procedure was stereotaxic implantation of ventral mesencephalic
tissue in the anterior, mid and post putamen on the side contralateral to the
most involved limb. 13 Patient three was a 50 year old male with stage III
Hoehn-Yahr PD pre-operative. During off periods he had severe rigidity,
moderate tremor, and hypokinesia immediately following FTT. Patient three
had an increase in PD symptoms followed by a significant decrease in time
spent in off phase. According to the patient, there was a decrease in rigidity.
However, the patient had a slight increase in muscle tone.
Patient four was a 60 year old male with stage III Hoehn-Yahr PD
previously. This patient had moderate resting tremor and severe rigidity.!3
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He also had marked hypokinetic movements. This patient spent 60% of his
day in the off phase. Following FTT, the patient had a "marked reduction of
both the number and duration of daily offperiods."13 He spent only 30% of
his day in the off phase. There were no significant improvements in rigidity
or tremor. Some gains were made in ann and hand functions up to the
seventh month but these improvements were not sustained through the 12th
month.
Following surgery, these researchers kept the patients' L-dopa dosages at
pre-operative levels to decrease the risk of improvements being credited to
changes in medication. 13 The conclusion of this research team was that
neural grafting has potential as a treatment for PD. However, the results do
not merit large clinical trials.
In an ongoing study by Madrazo et al,5 seven patients with PD received
FTT. Madrazo stated that follow up of these patients is very important. The
ultimate goal of FTT is to produce long lasting benefits. In a recently
published article, Madrazo described the status of two FTT PD patients, two
years post-surgery.
One patient was a 50 year old male diagnosed with PD nine years
previously. He had been receiving levadopa therapy at 1,000 mg/day.5 This
patient suffered from drug induced dystonia and dyskinesia. The second
patient was a 35 year old female who had PD for five years.
These patients received FTT two years previously. The progress of the
patients regarding L-dopa dosages was as follows; patient one went from
taking 1000 mg/day pre-operative to 500 mg/day at 24 months; patient two
had been taking 750 mg/day of L-dopa and at six months, her dosage was
250 mg/day, while at 24 months after surgery, it was 500 mg/day. This
implied a significant decrease in the patients daily L-dopa requirements. 5
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Time spent in the off phase decreased by 60% in patient one and by 50%
in patient two over the two year period. s Functionally, patient one had
"significant amelioration of rigidity, bradykinesia, postural imbalance and
gait disturbances. liS His tremor was also decreased. This patient was said to
be leading a normal life, following surgery, including going back to work.
At two years post FTT, patient two had shown some improvements. s She
had significant amelioration of only rigidity and bradykinesia, without
important changes in other signs. She is said to be able to perform
household tasks and to be of moderate clinical status.
In conclusion, Madrazo et al S stated that, regardless of the mechanism of
action, brain transplantation is affecting PD signs to a greater extent than
previous methods. The authors concluded that the usefulness of tissue
grafting for neurological diseases cannot be overlooked.
Additional research by Widner et al
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reported the technique utilized and

progress ofFTT in two patients with drug induced Parkinsonism. The major
difference between this study and the others reviewed was that in the drug
induced PD, there was no continuation of the disease process. The causative
agent was no longer present. For this reason, Widner et al may be doing a
more objective investigation of the viability ofFTT.
Patient one was a 43 year old male who developed severe Parkinsonism
following self-injection of the synthesized street drug }"1PTP in 1982.1-l
L-dopa therapy was causing increasingly severe side effects. This patient
needed extensive help with eating, dressing and personal hygiene. He had at
least six off periods each day with as little as 25% of his day in on periods.
This patient had pronounced hypokinesia, rigidity, and postural
abnormalities. Patient one was rated a stage IV and occasionally stage V on
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the Hoehn-Yahr PD scale. During defined "Off' periods he was unable to
open his eye-lids without help.
Patient two was a 30 year old female who also developed severe
Parkinsonism because of an MPTP drug injection.l4 She was becoming
increasingly intolerant of L-dopa therapy. This patient suffered from
continuous dyskinesia which rendered her almost completely incapacitated.
She had five or six off periods each day with 50 to 75% of the day in the on
phase. This patient required extensive help completing activities of daily
living. She was rated as a Hoehn-Yahr stage IV.
Six to eight week old fetal mesencephalic tissue from fetuses was
injected through a frontal burr hole. There were three placements in the
putamen and one in the caudate nucleus, bilaterally. At 24 months after
surgery, patient one had much more independence. 14 He was able to dress
and feed himself, and go to the bathroom independently. He also made trips
out of the home. His liOn" time increased to 50-75% of his day and his
Hoehn-Yahr rating went to a stage three. By 24 months, his rigidity was
virtually eliminated. His gait became smooth, with a return of natural ann
swmg.
Patient two had her L-dopa level reduced by 70% after 18 months.14 At

22 months after surgery, her dyskinesia was greatly reduced. Also, she had
"On" phase 50% of the day. She was then rated at a stage II to III on the
Hoehn-Yahr scale. She was able to feed herself without difficulty. Muscle
rigidity was ameliorated and she was able to ambulate with spontaneous am1
swmg.
The authors concluded that their two patients had made more extensive
gains than most patients to date. 14 They attributed their success to the fact
that the the patients received a larger amount of tissue bilaterally, and also
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that the patients had MPTP induced Parkinsonism as opposed to idiopathic
PD. This meant that their brain lesions were not progressive and only the
substantia nigra was affected. However, the researchers admitted that these
patients improvements were incomplete. Therefore, they felt further
research was needed before the treatment is adopted clinically.

CHAPTER 4
DISCUSSION AND DEBATE OF FTT

Research is being done all over the world to determine the efficacy of
neural transplantation. 10 At this point, FTT cannot be disregarded as a useful
treatment for progressive neurological diseases, namely PD. However,
neural transplantation for PD is still at an experimental stage and should not
be used clinically until more research is done. 10,12 This research is likely to
continue at the same pace as the increasing understanding of the pathology
of PD.1° Also, with increasing understanding of fetal development,
researchers will be able to distinguish the best donors.10 In theory, multi-site
implantations or perhaps a more precise placement of the graft may
influence further studies. Also a better understanding of graft survival may
produce a greater therapeutic response. There is the possibility of grafting
dopaminergic cells in combination with growth factors, to assure the grafts
integration into the existing tissue.
To date, much of the improvement seen in patients receiving FIT has
been antidotal. Subjective measures, whether on the part of the researcher or
the patient, were often the primary measure of success. A more rigid,
standard testing battery should be designed and followed closely both pre
and post operatively by all research teams. 6 ,14 Also, a more systematic
selection of the: 1) patients to receive the transplants 2) amount ofFT to be
used, and 3) FTT placement sites would make research more thorough. 13 ,14
At present, there are far too many variables in tht:;se studies. It is difficult to
16
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credit improvements soley to the procedure. 6 It may also be appropriate to
do the surgery on less involved patients. 8 Then perhaps, more functional
gains could be made.
The use of FTT for PD has become a highly debated topic. There are
those who feel the procedure is unethical and ineffective,7 while others
contend FTT has potential as a viable treatment for PD .16.17 In the following
paragraphs, some of the discussions and debates surrounding the use of fetal
tissue transplants in Parkinsons Disease (PD) is presented.
According to Rosenfeld et al, 7 fetal tissue transplant studies lacked
vigorous assessment and long-term follow-up . He believed that the clinical
applications of neurotransplantation for PD was premature. Rosenfeld stated
that, late in the course of the disease, symptoms cannot be controlled and
complications arise because of long-term Leva-Dopa therapy. For these
reasons, other types of therapy for PD need to be explored. According to
Rosenfeld, there have been eight studies of human fetal grafting in PD , with
a total of 50 cases. He contended that it would be difficult to interpret the
results of the studies to date because of the lack of uniformity in assessment
of responses and the often inadequate follow-up.
Rosenfeld's 7 theories as to why many of the grafts \vere failing included:
(a) insufficient quantities of tissue transplanted, (b) the fact that the disease
process ofPD attacks the newly grafted cells, (c) the possibility that the graft
site was not optimal, and (d) the initial insult to the tissue may cause
immediate but short term improvements. Rosenfeld concluded that neural
transplantation for PD is still in the experimental stages and should not be
used while many of the major questions remain unans\vered.
Larry Thompson 15 highlighted recent advances in fetal tissue
transplantation at the July 1992 4th International Symposium on Neural
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Transplantation. It was proposed that, currently, research of fetal tissue
transplants of PD was being done in a haphazard way. Right now, there are
15 research centers in 11 countries. The consensus was that research would
be more effective if there were only a few centers to undertake larger clinical
trials. This would promote more unifonn, systematic assessment of the
patients and procedures from before surgery through the long-tenn. Over
all, the consensus at the symposium was one of optimism regarding the
potential of fetal tissue transplantation as a viable treatment for PD.
Fahn 16 stated that there has been at least some benefit in humans given
fetal ventral mesencephalic implants, and in some patients there was
substantial benefit. Fahn stated that the most impressive results were those
of Widner et al,14 who studied patients with non-progressive MPTP-induced
PD. Fahn concluded that this study was important due to the fact that
patients maintained their improvements, indicating the grafts were surviving
and growing.
However, Fahn 16 noted that PD is a progressive disease and the fate of
the implanted tissue may be the same as that of the original dopamine
producing cells. This author stated that the most dramatic functional benefit
of the three studies he critiqued was a statistically significant decrease in off
time and an increase in on time. Also, the reduction of L-dopa dosage was
noteworthy. Fahn disputed the notion that the insult to the tissue and
subsequent healing was the basis for improvement. He contended that
adrenal medullary grafts caused similar damage with no clear equivalent
benefit. Fahn concluded that this surgical procedure remained
investigational but showed optimistic promise for future use. However,
reports with longer follow-up are essential.
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According to Christopher Goetz et al,17 humans with PD who have
received fetal nigral transplants to the striatum, have improved clinically_
He contended the attraction of surgery is its highly focused targeting, ideally
suited to a disease like PD in which neurodegeneration is also largely
circumscribed.
Sue Fletcher 1 stated that early results of fetal tissue transplantation are
encouraging. She contended it is unclear, however, if the benefits are the
result of a placebo effect or another non-specific action of the graft.

CHAPTERS
POLITICAL AND ETHICAL ISSUES

This paper would not be complete without addressing the political and
ethical issues surrounding FTT. The political influence has been a
withholding of public funds for research. From 1988 through 1993, there
was a ban on funding of fetal tissue research in the U.S.18 Consequently,
fetal tissue research done in the U.S. has been privately funded. 19 The ban
was originally placed by the Reagan administration to avoid any indication
that they encouraged abortion. 19 After the moritorium was in effect, a
Human Fetal Tissue Transplantation Research (HFTTR) Panel was
appointed to study the matter. 7 Experts in medicine, law and ethics made up
the 21 member team. In late 1988, the panel "found it acceptable public
policy to fund the research. "19 However, the recommendation was not
implemented by the Bush administration, and the moratorium was continued
indefinitely.20 As recently as February, 1993, the Clinton administration
lifted the ban on public funding of FTT research. 18
For FTT experiments to take place, an abortion must have occurred. This
is the cause of much ethical debate. Anti-abortion proponents contend that
this research will encourage ambivalent pregnant women to choose
abortion. 19 If these women think that having an abortion would benefit
someone else, their decision may be swayed. Perhaps a woman would be
pressured to conceive in order to supply fetal tissue for a family member
who has PD.!
20
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Most supporters of the research believe that "absolute separation of the
tissue harvesting from the donation procedure is an essential requirement. "7
Kassirer et al 19 argued that FTT research does not show "support of
abortion, any more than transplanting organs from murder or accident
victims constitutes support for murder or accidents.
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A woman's decision to

have an abortion involves a great deal of personal consideration. ls
According to Kassirer et al,19 it is not the place of the government to
scrutinize the motives of a woman contemplating abortion.
Nevertheless, the HFTTR panel developed safeguards to prevent a
pregnant woman's decision, to have an abortion, from being influenced by
the possibility of helping another. The guidelines are as follows: 1) A
woman should not be approached about the issue of FTT until she has made
her decision to have an abortion; 2) The donor and recipient must not know
one another; 3) Fetal tissue should not be donated for a specific patient;
4) There should be no financial incentive either for the woman or for the
facility.19 It is imperative that the decision to have an abortion and the
decision to donate tissue are two separate entities.
There is also the concern about supply and demand. With the continued
research on fetal implantation in neurological diseases such as PD and
Alzheimer's, will there be enough tissue to go around? According to
Fletcher et all, "in the United States, it is estimated that l.6 million
pregnancies are voluntarily terminated each year, and approximately 78% of
these occur between the 6th and lIth weeks of pregnancy, which would
provide adequate supplies of fetal tissue for the present demand.

II

CHAPTER 6
CLINICAL APPLICATIONS AND CONCLUSIONS

PD is a progressive, neuromuscular disease that effects the motor
planning areas of the brain, namely the substantia nigra and basal ganglia.
PD presents with slowed movement, muscle rigidity, resting tremor and
postural abnormality. To date there is no cure for PD, however, it is
controlled primarily through drug therapy.21
Physical therapy (PT) can be instrumental in helping PD patients improve
functional ability and combat subsequent deformities. 22 According to
O'Sullivan et al,2 physical therapy treatment ofPD usually consists of:
(1) relaxation exercises to reduce muscle tone, (2) range of motion exercises

to maintain functional mobility, (3) gait training to increase arm swing and
step length, (4) strengthening exercises to prevent muscle atrophy, and
(5) respiratory exercises to maintain the plyability of chest wall musculature.
In a study by Formisano et al,23 it was found that, for PD patients, PT
treatment along with drug therapy was effective in improving functional
performance. The study compared motor performance test results of 16 test
patients and 17 control patients over a four month period. The test patients
received physical therapy together with drug therapy, while the control
groups receive only drug therapy. After four months, the patients receiving
physical therapy rated higher on the motor performance tests. There was
also a statistically significant difference in the daily activity scale and
walking tests.
22

23

FTT could have a great influence on physical therapy treatment of
patients with PD. Early intervention is the key to the efficacy of physical
therapy in PD. 23 Those receiving FTT surgery may then enter a
rehabilitation facility to maximize potential gains. These patients could be
intensively trained in gait, postural mobility and other functional activities
immediately following surgery. Also, in many of the studies outlined,
patients have continued to make gains over as long a period as 24 months. 5,6
Continued PT has been found to be benificial in helping PD patients
maintain a high degree of independence as long as possible,23 This suggests
that these patients would continue to benefit from further physical therapy as
the FTT grafts integrate into the surrounding tissue.
There is no literature to date on the physical therapy treatment of PD
patients receiving FTT. This is perhaps due to the fact that there have been
only 50 patients in the world who have received FTT.1 However, it is noted
that in the follow-up of these patients, there has been no mention of
rehabilitation. 5• 14 Even with this small number of subjects, individual case
studies could be done to illustrate the efficacy of PT for these patients.
With continued research in the area ofFTT surgery, more emphasis could
be placed on translating the neurological improvement into function.
Perhaps these patients would make even greater functional gains with the
incorporation of a comprehensive rehabilitation program following FTT
surgery.
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